Multiplex point-of-care diagnostics platform
Reinventing diagnostics
from the ground up.
Platform technology for scalable, high-performance point-of-care testing — lab-quality answers wherever care happens.
About us
Solving the upstream problem in diagnostics.
Thrixen is a Singapore-based biotech/medtech company reinventing rapid point-of-care diagnostic testing from the ground up. Where others optimise the downstream assay, we address the root: the binding molecule at the heart of every protein-based test.
By replacing antibodies with bioengineered Affinex® binders, we deliver faster, simpler and smarter diagnostics — affordable, and accessible wherever care happens.
of the world's population has little or no access to diagnostics — leading to delayed treatment, misdiagnosis and avoidable deaths.
Under-innovated
Protein-based diagnostics underpin broad clinical use, yet remain antibody-dependent and largely unimproved.
From platform to outcome
Better binders lead to better tests — and better tests mean the right answer, sooner, for more people.
Clearer insights
A complete clinical picture from a single test.
Faster answers
Lab-quality results in minutes at the point of care.
Better outcomes
Simpler workflows and optimised treatment pathways.
Our technology
One system. Three integrated innovations.
Reinventing the assay from the ground up — pairing bioengineered binders with a multiplex assay and a portable reader to deliver the complete clinical picture in a single test.
Bioengineered binders
Purpose-built binders replace antibodies at the heart of the test — engineered for superior diagnostic performance and scalable production.
Multi-domain multiplex assay
Three questions in one test — direct antigen detection, isotype-specific serology and host immune response — for the complete clinical picture.
Portable reader
A palm-sized, battery-powered reader delivers a full multiplex result from a fingerprick sample in ~10 minutes.
High-affinity binders, specifically bioengineered for diagnostics.
No cross-reactivity
Stable in extreme temperature & pH
Scalable, cost-effective productionRobust multiplexing
Clear IP & patentability
Controllable engineering process3 patents pending, with 5+ more in the pipelineLicensing
Our Affinex® binders are available for licensing across research and diagnostic applications.
Performance
Performance that outpaces best-in-class antibodies on every axis.
Up to 10×
higher sensitivity than best-in-class antibodies
5 hrs
stable at 90°C — up to 1000× more stable
2–7×
faster production period
>10×
lower production cost
The cellulose multiplex cassette
A fingerprick sample in, a full multiplex panel out — a simple workflow built for real-world, low-resource settings.
Whole blood, no processing
Runs directly on whole blood — no centrifuge, spinning or sample prep required.
Metered capillary channel
A precision capillary draws an exact, metered volume straight into the cassette.
No additional consumables
Everything needed for the test is self-contained — nothing extra to buy or stock.
Simple & biosafe by design
A sealed, closed workflow that is easy to run and minimises exposure to the sample.
The point-of-care reader
A portable, battery-powered reader turns that same sample into a multiplex result in ~10 minutes — no lab infrastructure required.
Result in ~10 minutes
From fingerprick to a full multiplex readout at the point of care.
Portable & battery-powered
Palm-sized and self-powered — take it wherever care happens.
Lab-quality & affordable
Central-lab performance without central-lab cost or infrastructure.
Reconfigurable panels
One reader runs an expanding library of panels — reconfigure the test, not the hardware.
Multi-domain multiplex assay
Three diagnostic questions, answered in a single test.
Where a conventional test measures one thing, the Thrixen assay interrogates three complementary domains at once — resolving not just whether a pathogen is present, but how the body is responding to it.
Direct antigen detection
Detects pathogen proteins directly in the sample, confirming an active infection in real time.
Isotype-specific serology
Distinguishes antibody isotypes to place the immune response on a timeline — recent versus established.
Host immune response
Measures host biomarkers that reveal how the body is reacting — informing severity and triage.
Coverage across clinical areas
The team
Scientists and operators building the future of diagnostics.
A team spanning protein engineering, microfluidics, medical-device development and commercial growth — backed by advisors from MIT, NTU and beyond.
Operating team
Shavit N Clein
Over 15 years of entrepreneurial experience across payments, media, AI and healthcare, with expertise in strategy, operations and new business development. He has led international expansion and managed relationships with global brands, and mentors ventures at the NUS Medicine Digital Advanced Technology Accelerator.
Patthara Kongsuphol, PhD
A biomedical engineer with over 15 years of experience innovating biosensors for DNA and protein detection across paper, polymer, silicon and conductive substrates. During COVID-19 she led development of a rapid test detecting SARS-CoV-2 neutralising antibodies, navigating R&D, manufacturing and clinical trials. She oversees all innovation at Thrixen.
Jia Huan (Emma), PhD
Earned her PhD in structural biology at NTU Singapore and is an experienced protein engineer specialising in diagnostic test development. With experience across research institutions and biotech start-ups, she is committed to translating science into technologies that address real-world health challenges.
Anshika Sharma, PhD
Experienced scientist specialising in protein engineering and infectious disease diagnostic development. Skilled in verification and validation processes to ensure high-quality outputs in biomedical applications.
Irvine Ong, PhD
Leads in-vitro diagnostic assay and reader development at Thrixen, integrating cross-disciplinary expertise in microfluidics, biosensors and paper manufacturing gained across industry and academia in Europe and Singapore.
Ben Boedeker, DVM, MD, PhD
Previously Vice Chair for Anesthesia Research at the University of Nebraska School of Medicine, holding the rank of full professor, and staff anesthesiologist at the Omaha VA Medical Center. He served as a military research physician, retiring after 30 years with the rank of Colonel.
Board of directors & advisors
Peter Preiser, Prof
Chair of the School of Biological Sciences and professor of molecular genetics and cell biology at Nanyang Technological University, Singapore. He specialises in the study of the malaria parasite and heads the team that discovered a route to a possible vaccine.
Hadley Sikes, Prof
Professor of Chemical Engineering at MIT, working in biomolecular engineering, applications of redox chemistry, clinical diagnostics and molecular biotechnology.
Megan McBee, PhD
Scientific Director of the Antimicrobial Resistance IRG at the Singapore-MIT Alliance for Research & Technology Centre; former biotech start-up director.
Ara Tavitian, MD
Founder & Managing Partner at 22Health Ventures and a physician-entrepreneur; previously founder of Vista Healthcare.
John Ballantyne, PhD
Co-founder and former Chief Scientific Officer of Aldevron, the world-leading plasmid-DNA CDMO, through to its exit to Danaher.
Extended team
Yaw Bia Tan, PhD
Protein enthusiast with expertise in structural biology and protein sciences. Working on protein engineering and characterisation for diagnostics applications.
Yuzhou Yang, PhD
Specialisation in plant biotechnology and microbiology. Currently focused on protein engineering and diagnostic assay optimisation.
Thrixen is supported by
Contact us
Let's talk diagnostics.
Whether you're a clinical partner, investor or collaborator, we'd like to hear from you.
Office
70 Shenton Way, #11-01
Eon Shenton, Singapore 079118
Follow
Follow us on LinkedIn